# A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

> **NCT01627106** · PHASE4 · WITHDRAWN · sponsor: **Advanz Pharma**

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Vernakalant
- **DRUG:** Amiodarone

## Key facts

- **NCT ID:** NCT01627106
- **Lead sponsor:** Advanz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-09
- **Primary completion:** 2016-02
- **Final completion:** 2016-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627106, "A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01627106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*